Conbercept: A Breakthrough in Diabetic Macular Edema Treatment - New Hope for Vision Preservation

Could Conbercept Revolutionize DME Treatment?

Conbercept in Diabetic Macular Edema: Clinical Advances and Future Directions

Diabetic Macular Edema (DME) remains one of the most vision-threatening complications of diabetes mellitus, affecting approximately 30% of the over 537 million individuals with diabetes globally. The condition, characterized by fluid accumulation in the macula due to breakdown of the blood-retinal barrier (BRB), poses significant challenges for ophthalmologists and patients alike. While anti-VEGF therapies have revolutionized DME treatment since 2005, issues including drug resistance in some patients and the burden of monthly injections leading to decreased compliance persist. In this context, Conbercept, a novel recombinant VEGF receptor-antibody fusion protein developed by Chengdu Kanghong Pharmaceutical Group, has emerged as a promising therapeutic option, approved for DME treatment in China in 2019 and subsequently included in the national medical insurance program.

Why Is Diabetic Macular Edema a Pressing Concern?

Conbercept's molecular design specifically addresses the pathophysiological mechanisms underlying DME. The 143 kDa fusion protein incorporates key functional domains from VEGFR1 (Ig-like domain 2) and VEGFR2 (Ig-like domains 3-4), enabling it to target both VEGF-A and placental growth factor (PlGF), critical mediators in DME pathogenesis. The addition of a human IgG1 Fc fragment enhances stability and extends its vitreous half-life to approximately 4.2 days—45% longer than ranibizumab. This pharmacokinetic profile enables Conbercept to sustain therapeutic concentrations for over 34 days following a single 0.5 mg intravitreal injection, potentially allowing for less frequent dosing and improved patient compliance. The large molecular structure also contributes to minimal systemic absorption, with serum concentrations remaining below 0.1 ng/mL, thereby reducing risks of systemic anti-VEGF-related adverse events.

How Does Conbercept Work at the Molecular Level?

DME pathogenesis involves multiple interconnected mechanisms triggered by chronic hyperglycemia. First, excessive VEGF-A release directly increases vascular permeability and causes capillary leakage. Second, inflammatory factors such as IL-6 and TNF-α work synergistically with PlGF, activating microglial and Müller glial cells and disrupting fluid transport balance through abnormal AQP11 expression. Third, oxidative stress and advanced glycation end-products (AGEs) accumulation damage endothelial tight junctions, leading to microaneurysm formation and lipoprotein extravasation. Conbercept targets these pathways through multiple mechanisms: it forms high-affinity interactions with VEGF-A via its VEGFR2 domain, directly inhibiting vascular leakage; it specifically binds VEGF-B through VEGFR1, reducing inflammatory cell infiltration; and it acts as a "decoy receptor" for PlGF, neutralizing its inflammatory effects. This multi-target approach creates a comprehensive blockade of the key pathogenic pathways in DME.

What Do Clinical Trials Tell Us?

The SAILING study, a pivotal multicenter, randomized, double-blind Phase 3 clinical trial enrolling 251 DME patients, demonstrated Conbercept's clinical efficacy over conventional laser photocoagulation. At the 12-month mark, the Conbercept group exhibited significant visual acuity improvement, while the laser group showed no meaningful BCVA changes. Moreover, the proportion of patients achieving visual gains of ≥15, ≥10, and ≥5 letters was significantly higher in the Conbercept group at both 6 and 12 months compared to laser therapy. These results affirm Conbercept's ability to not only arrest disease progression but substantively improve visual function in DME patients.

Could Conbercept Offer Benefits Beyond Visual Acuity?

Recent research has also uncovered a novel mechanism by which Conbercept reduces hard exudates in diabetic retinopathy. Clinical observations show that three consecutive intravitreal injections significantly decrease hard exudate area in DME patients. Mechanistic studies reveal that Conbercept inhibits the VEGF/VEGFR2 signaling pathway, reducing oxidative stress and inflammatory responses in retinal Müller cells under hyperglycemic conditions. This activates the PPARγ-CD36 axis, upregulating CD36 expression and enhancing Müller cells' capacity to phagocytose oxidized low-density lipoprotein, the primary component of hard exudates. This finding adds another dimension to Conbercept's therapeutic profile beyond its anti-permeability effects.

How Can Treatment Protocols Be Optimized?

Regarding treatment protocols, research has focused on optimizing regimens to balance efficacy with treatment burden. The standard recommended dose is 0.05 mg (0.05 ml injection volume), with the "3 + PRN" regimen (three consecutive monthly injections followed by pro re nata dosing) established as effective. Comparative studies between "6 + PRN" and "3 + PRN" approaches revealed that extending the initial intensive treatment phase to six injections significantly improves outcomes and reduces subsequent injection requirements. Additionally, emerging research utilizing generative adversarial networks (GANs) for OCT image analysis is enabling more personalized treatment approaches, potentially identifying distinct response patterns early in therapy to guide individualized dosing strategies.

Is Long-Term Safety Assured?

Safety profiles from multiple studies have consistently demonstrated Conbercept's favorable risk-benefit ratio. Long-term treatment (24 months) resulted in intraocular pressure elevation in only about 12.8% of patients, with no cases progressing to secondary glaucoma. No severe endophthalmitis or vitreous hemorrhage was reported across studies, and injection-related adverse events were typically mild and transient. Systematic reviews covering 12-month treatment periods found no arterial thromboembolic events or significant increases in hypertension or thrombotic risk. Notably, even in DME patients with comorbid diabetic kidney disease, Conbercept did not exacerbate renal function, with laboratory indicators remaining stable throughout treatment.

Can Combined Approaches Enhance Outcomes?

Current combined therapy regimens primarily involve anti-VEGF drugs with laser or steroid treatments for DME, aiming to complement drug efficacy and improve outcomes in complex cases. Studies show that for patients with severe non-proliferative diabetic retinopathy (NPDR) combined with macular edema, intravitreal Conbercept (IVC) combined with panretinal photocoagulation (PRP) effectively improves vision, reduces macular edema, enhances retinal microcirculation, and significantly lowers aqueous humor levels of SDF-1 and VEGF. The combination of IVC with subthreshold micro-pulse laser (SMLP) has proven equally effective as IVC alone in reducing central macular thickness and improving BCVA, while significantly reducing the number of required injections. Emerging combination approaches include Conbercept with calcium dobesilate to improve retinal microcirculation and potentially reduce injection frequency, and exploration of combinations with anti-Ang-2 agents for more comprehensive target coverage.

How Does Conbercept Compare with Other Agents?

When compared with other anti-VEGF agents, Conbercept demonstrates several competitive advantages. Its broader target coverage (VEGF-A/B and PlGF) mirrors aflibercept's profile but exceeds ranibizumab and brolucizumab, which target only VEGF-A. Conbercept's binding affinity for VEGF-A (KD: 0.3pM) significantly surpasses ranibizumab (46pM) and is comparable to aflibercept (0.497pM). In clinical outcomes, the SAILING study showed a 12-month BCVA gain of +8.2 letters, comparable to aflibercept's +9.4 letters in VIVID/VISTA and ranibizumab's +6.8 letters in REFINE. Pharmacoeconomic analyses within China's healthcare system indicate moderate first-year treatment costs with outstanding cost-effectiveness ratios compared to alternatives.

What Challenges Remain in Current Research?

Despite these promising results, several research limitations merit consideration. Most clinical trials have been limited to 200-500 participants with moderate baseline visual acuity and without severe comorbidities, potentially limiting generalizability to complex real-world scenarios. Follow-up periods typically spanning 12-24 months provide insufficient data on long-term efficacy and safety beyond five years. Additionally, approximately 30% of DME patients exhibit poor response to Conbercept, yet research into drug resistance mechanisms remains superficial, focusing primarily on VEGF pathway-related factors rather than non-VEGF-dependent mechanisms like oxidative stress or advanced glycation end product accumulation.

Combination therapy approaches have shown promise but require more robust evidence. Small-sample, single-center studies have investigated Conbercept combined with treatments including micropulse laser, panretinal photocoagulation, and calcium dobesilate. While preliminary results suggest enhanced efficacy and reduced injection frequency, the absence of large-scale multicenter randomized controlled trials limits definitive conclusions and guideline recommendations. Parameters such as optimal timing for combination therapy initiation remain unclear, leaving clinicians with considerable subjective judgment in treatment selection.

Are the Economics of Long-Term Treatment Sustainable?

Current studies on Conbercept also lack comprehensive health economics and accessibility research. While the efficacy and safety profiles are well-documented, few studies address the health economics aspects of long-term treatment, which involves repeated injections and substantial costs affecting patient compliance. There is a notable absence of cost-effectiveness analyses comparing different treatment regimens and accessibility studies across various healthcare payment systems. This gap in data hampers evidence-based healthcare policy formulation and cost-effective clinical treatment decisions, particularly for implementation in primary healthcare settings.

What Directions Will Future Research Take?

Future research directions should address these limitations through several approaches. Expanding trial scope to include diverse ethnicities, regions, and comorbidity profiles would enhance generalizability and potentially overcome the challenges that led to the PANDA global trial's limited success. Precision medicine approaches incorporating genetic testing and biomarker analysis could identify polymorphisms in drug metabolism and target genes, enabling customized dosing regimens. Dynamic monitoring through advanced imaging techniques like OCT and fluorescein angiography could further refine personalized treatment strategies, avoiding both overtreatment and undertreatment.

Do These Findings Suggest New Avenues for Personalized Medicine?

Innovative combination therapies targeting complementary pathways present another promising avenue. Drugs targeting the IL-6 receptor (e.g., Tocilizumab) have shown efficacy for refractory DME in clinical trials, while PPAR-γ agonists could improve blood-retinal barrier function through metabolic regulation and anti-inflammatory effects. Novel drug delivery systems, including biodegradable intravitreal implants, might significantly reduce injection frequency and improve treatment adherence. Artificial intelligence applications for image analysis could enable more precise assessment of retinal lesion severity and treatment efficacy, potentially detecting subtle changes before clinical manifestation.

How Will Conbercept Shape Clinical Practice?

Could the multi-targeted approach of Conbercept addressing both VEGF and PlGF pathways fundamentally alter treatment algorithms for DME, particularly for patients with inflammatory components to their disease? How might advanced imaging biomarkers and genetic profiling transform our ability to predict treatment response and design truly personalized dosing regimens? What additional safety and efficacy data would be necessary to position Conbercept as a global first-line therapy for DME?

In conclusion, Conbercept represents a significant advancement in DME management, with its multi-target molecular design, extended intravitreal half-life, and demonstrated efficacy in improving visual outcomes and reducing macular edema. While current evidence supports its use, particularly in Asia-Pacific regions as reflected in APAO 2023 guidelines, addressing research limitations through larger international trials, mechanism-based studies of treatment resistance, and exploration of optimized combination therapies will be essential to fully realize its therapeutic potential. The integration of precision medicine approaches and innovative delivery systems may further enhance Conbercept's role in preserving vision and improving quality of life for the growing population of patients with diabetic macular edema worldwide.

Summary

Conbercept represents a significant advancement in treating Diabetic Macular Edema (DME), affecting approximately 30% of diabetes patients worldwide. This novel fusion protein, developed by Chengdu Kanghong Pharmaceutical Group, demonstrates superior efficacy through its multi-targeted approach, binding both VEGF-A and PlGF. Clinical trials, particularly the SAILING study, showed significant visual acuity improvements compared to conventional laser treatment. The drug's extended half-life of 4.2 days allows for less frequent dosing, while its safety profile remains favorable with minimal systemic absorption. Research indicates additional benefits, including reduction of hard exudates through novel mechanisms. Despite promising results, challenges remain, including treatment resistance in some patients and the need for more comprehensive long-term studies. Future directions focus on personalized medicine approaches, combination therapies, and innovative delivery systems to optimize treatment outcomes.